AUSTIN, Texas, June 3, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private equity firm, announced today that it has completed the previously announced acquisition of the dental segment ("HuFriedyGroup" or the "Company") of STERIS plc (NYSE:STE) ("STERIS").
Founded in 1908, HuFriedyGroup is a leading global manufacturer of high-quality instruments, infection prevention products, instrument management systems, and conscious sedation products for the dental industry. The Company has industry leading brands, including Hu-Friedy, Crosstex, Omnia, and Accutron. Headquartered in Chicago, Illinois, the Company serves customers in ~100 countries, and is supported by a base of ~1,500 employees across over 20 global manufacturing facilities and locations. The Company has built a strong reputation in the industry for its outstanding quality, broad product offerings, efficient workflow solutions, and ergonomic instrument designs.
Spencer Moore, Managing Director of Peak Rock Capital, said, "HuFriedyGroup's differentiated brands, high-quality product offerings, strong customer base, and outstanding team make this a highly compelling investment opportunity. We look forward to partnering with the management team and employees to drive further new product innovation and accelerated organic growth. We're also excited to help the team pursue complimentary acquisitions to extend the product and brand portfolio."
Anthony DiSimone, Chief Executive Officer of Peak Rock, added, "This investment exemplifies Peak Rock's deep experience and capability in executing complex carve-out transactions. It also highlights our continuing efforts to expand our investments in medical technology and global manufacturing businesses. We believe that HuFriedyGroup represents an excellent platform for growth through near-term organic initiatives and strategic acquisitions."
ABOUT HUFRIEDYGROUP
HuFriedyGroup is a leading global manufacturer of dental instruments, instrument management systems, infection control products, and conscious sedation equipment and accessories under the HuFriedy, Crosstex, Omnia, and Accutron brands. Its 10,000-plus products are known for their precision, performance, longevity, reliability, and quality. HuFriedyGroup helps dental professionals be the best in practice by bringing together world-class products, services, education, and communities that result in superior clinician performance, clinical outcomes, and enhanced safety for clinicians and patients. Founded in 1908 and headquartered in Chicago, HuFriedyGroup products are distributed in ~100 countries, and is supported by a base of ~1,500 employees across over 20 global manufacturing facilities and locations. For more information visit https://www.hufriedygroup.com.
ABOUT PEAK ROCK CAPITAL
Peak Rock Capital is a leading middle-market private investment firm that makes equity and debt investments in companies in North America and Europe. Peak Rock's equity investment platform focuses on opportunities where it can support senior management to drive rapid growth and profit improvement, with expertise in corporate carve-outs and partnering with families and founders seeking first-time institutional capital. Peak Rock's credit platform invests across capital structures, with a broad mandate to provide flexible, tailored capital solutions to middle-market and growth-oriented businesses. Peak Rock's real estate platform makes equity and debt investments in small to mid-sized real estate assets in attractive, growing geographies. For further information about Peak Rock Capital, please visit www.peakrockcapital.com.
Media Contact:
Daniel Yunger
Kekst CNC
(212) 521-4800
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$214.34 |
Daily Change: | -1.43 -0.66 |
Daily Volume: | 476,608 |
Market Cap: | US$21.160B |
November 06, 2024 August 26, 2024 August 06, 2024 February 07, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB